- Associated Press - Thursday, December 23, 2010

CONCORD, N.H. (AP) — New Hampshire is getting $1.7 million from two prescription drug manufacturers that billed the state’s Medicaid program for substandard or improperly marketed medications.

GlaxoSmithKline will pay the state $1.24 million because four drugs it marketed here between 2001-2005, including Paxil CR, did not meet strength and purity standards set by the FDA.

Drug maker Novartis will pay the state $489,000 because it promoted its anti-epileptic drug, Trileptal, for unapproved uses such as treatment of bipolar disorder and neuropathic pain.

Senior Assistant Attorney General Jeff Cahill said no New Hampshire patients suffered harm as a result of the drug frauds.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide